Ian Cleminson, Innospec's (NASDAQ: IOSP) Executive Vice President and Chief Financial Officer, executed multiple sales of Innospec common stock on February 27, 2026. In aggregate, Cleminson disposed of 2,380 shares in transactions that took place at prices ranging from $75.5001 to $77.0713, yielding proceeds of roughly $182197.
The transactions were reported in two weighted-average tranches. One tranche comprised 1,149 shares sold at a weighted average price of $76.30. The remaining 1,231 shares were sold at a weighted average price of $76.79. Following these sales, Cleminson's direct holdings in Innospec stand at 20,357 shares.
Market context included in the report notes that Innospec's share price has declined by approximately 24% over the trailing 12 months. At the time of the filing, the stock was trading at $72.11, trading close to its 52-week low of $70.10. The write-up cites InvestingPro analysis, which characterizes the stock as appearing undervalued at current levels and points readers to the platform's Pro Research Report for more comprehensive assessment.
Summary of the transactions
- Date of sales: February 27, 2026.
- Total shares sold: 2,380.
- Proceeds: approximately $182197.
- Price range: $75.5001 to $77.0713.
- Weighted-average tranches: 1,149 shares at $76.30; 1,231 shares at $76.79.
- Shares held after sale: 20,357 shares.
Context and valuation note
The report highlights the recent downward movement in Innospec's share price over the past year - an approximate 24% decline - and situates the current quotation of $72.11 near the 52-week low of $70.10. It cites InvestingPro's finding that the stock appears undervalued at the present price, and references the platform's Pro Research Report for readers seeking additional analysis.
Key points
- Senior executive Ian Cleminson sold 2,380 Innospec shares on February 27, 2026, in several transactions that produced about $182197.
- After the transactions, Cleminson is recorded as owning 20,357 shares of Innospec common stock.
- The company's shares have fallen roughly 24% over the last year and were trading at $72.11, close to a 52-week low of $70.10; InvestingPro analysis included in the report indicates the stock appears undervalued.
Risks and uncertainties
- No motive for the sales is provided in the disclosure, leaving the reason for the transactions unspecified.
- The company's stock has experienced a material decline over the past year (about 24%), indicating price volatility and uncertainty for investors.
- Valuation assessments differ: while the report references an InvestingPro view that the stock appears undervalued, that assessment may not reflect all market perspectives and readers are directed to the Pro Research Report for further detail.
The item presents the factual record of the insider transactions and current market metrics cited in the filing and accompanying analysis. Readers seeking deeper valuation or strategy guidance are referred to the InvestingPro Pro Research Report noted in the disclosure for expanded coverage.